Advertisement

Pharmaceutical Research

, Volume 12, Issue 9, pp 1385–1387 | Cite as

Influence of Surface Properties on the Inflammatory Response to Polymeric Nanoparticles

  • Rocío Fernández-Urrusuno
  • Elias Fattal
  • Dominique Porquet
  • Jeanne Féger
  • Patrick Couvreur
Note
nanoparticles inflammation polystyrene poly(D,L lactic) acid poloxamers polyethylene glycol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    H. Baumann and J. Gauldie. The acute phase response. Immunol. Today. 15:74–80 (1994).Google Scholar
  2. 2.
    N. P. Ziats, K. M. Miller, and J. M. Anderson. In vitro and in vivo interactions of cells with biomaterials. Biomaterials 9:5–13 (1988).Google Scholar
  3. 3.
    J. Jozefonvicz and M. Jozefowicz. Blood-contracting polymers. In S. Dimitriu (ed.), Polymeric Biomaterials, Marcel Dekker, New York, 1994, pp. 349–371.Google Scholar
  4. 4.
    R. Fernandez-Urrusuno, E. Fattal, D. Porquet, J. Feger, and P. Couvreur. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol. Appl. Pharmacol. 130:272–279 (1995).Google Scholar
  5. 5.
    L. Illum, S. S. Davis, R. H. Muller, E. Mak, and P. West. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer Poloxamine 908. Life Sci. 40:367–374 (1987).Google Scholar
  6. 6.
    R. H. Muller and K. H. Wallis. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 89:25–31 (1993).Google Scholar
  7. 7.
    D. Bazile, T. Verecchia, M. T. Bassoulet, and M. Veillard. Ultradispersed polymer systems with rate and time control. Yakuzaigaku. 53:10–13 (1993).Google Scholar
  8. 8.
    H. Fessi, J. P. Devissaguet, and F. Puisieux, inventors; Procédé de preparation de systèmes colloidaux dispersibles d'une substance sous forme de nanocapsules. European Patent Appl 0274961. Al, 1988 July 20.Google Scholar
  9. 9.
    D. Biou, M. Daveau, O. Rigal, M. Hiron, D. Porquet, and J. P. Lebreton. An enzyme-linked immunoassay for the measurement of rat α1-glycoprotein synthesized by cultured hepatocytes. J. Immunol. Methods. 125:1–4 (1989).Google Scholar
  10. 10.
    I. Kushner. Regulation of the acute phase response by cytokines. Perspect. Biol. Med. 36:611–622 (1993).Google Scholar
  11. 11.
    J. Schnyder and M. Bagglioni. Role of phagocytosis in the activation of macrophages. J. Exp. Med. 148:1449–1457 (1978).Google Scholar
  12. 12.
    J. Janatova, A. K. Cheung, and C. J. Parker. Biomedical polymers differ in their capacity to activate complement. Complement Inflammation 8:61–69 (1991).Google Scholar
  13. 13.
    D. Labarre, M. Vittaz, G. Spenlehauer, D. Bazile, and M. Veillard. Complement activation by nanoparticulate carriers. Proc. Int. Symp. Control. Rel. Bioact. Mater. 21:91–92 (1994).Google Scholar
  14. 14.
    S. Tomlinson. Complement defense mechanisms. Curr. Opin. Immunol. 5:83–89 (1993).Google Scholar
  15. 15.
    M. M. Frank, and L. F. Fries. The role of complement in inflammation and phagocytosis. Immunol. Today. 12:322–326 (1991).Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Rocío Fernández-Urrusuno
    • 1
  • Elias Fattal
    • 1
  • Dominique Porquet
    • 2
  • Jeanne Féger
    • 2
  • Patrick Couvreur
    • 1
  1. 1.Université Paris XI, Faculté de Pharmacie, Laboratoire de Physico-Chimie-Pharmacotechnie-BiopharmacieChâtenay-MalabryFrance
  2. 2.Université Paris XI, Faculté de Pharmacie, Laboratoire de Bio-chimieChâtenay-MalabryFrance

Personalised recommendations